Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: etanercept; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Rumination
Interventions: Mindfulness (Headspace) App, Active Control Condition ("Recharge" condition delivered in Headspace app); Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 13 Years to 18 Years
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Cramps, Muscle Cramp
Interventions: Behavioral intervention one, Behavioral intervention two; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 3 more

Conditions: Carcinoma, Hepatocellular
Interventions: Regorafenib in combination with pembrolizumab, Loco-regional therapy; Drug · Procedure
Lead sponsor: Translational Research in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Lateral Canthal Lines, Crow's Feet
Interventions: botulinum toxin, Type A, Vehicle; Biological
Lead sponsor: Eirion Therapeutics Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Aggressive Systemic Mastocytosis (ASM), SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD), Mast Cell Leukemia (MCL), Smoldering Systemic Mastocytosis (SSM), Indolent Systemic Mastocytosis (ISM) ISM Subgroup Fully Recruited
Interventions: Interview; Other
Lead sponsor: Adelphi Values LLC; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Dato-DXd; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more

Conditions: Omega-3 Fatty Acids, Pediatric Bipolar Disorder, Adolescent Bipolar Disorder, Magnetic Resonance Spectroscopy Imaging
Interventions: Omega-3 Fatty Acid, Placebo; Dietary Supplement · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 12 Years to 18 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypovitaminosis D
Interventions: Cholecalciferol, Placebo; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Small Cell Lung Cancer
Interventions: Amrubicin, Topotecan; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 61
States / cities: Muscle Shoals, Alabama • Tucson, Arizona • Little Rock, Arkansas + 57 more

Conditions: Healthy Adults
Interventions: active anodal tDCS, sham tDCS; Device
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 35 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Social Cognition, Expressed Emotion
Interventions: Oxytocin, Placebo; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Solid Tumor
Interventions: 5-FU, Atezolizumab, Bevacizumab, Gemcitabine, Leucovorin, Nab-Paclitaxel, Oxaliplatin, Capecitabine, Cisplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 12
States / cities: Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more

Conditions: Healthy
Interventions: ARV-471, Rosuvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Abdomenal Wound Trauma
Interventions: RENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metabolic Syndrome, Heart Failure
Interventions: Not listed
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 59 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Hematopoietic Stem Cell Transplantation
Interventions: Blood Draw; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pulmonary Arterial Hypertension
Interventions: JNJ-67896049; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: La Jolla, California • Anderson, South Carolina • Dallas, Texas

Conditions: Diabetes, Gastric Bypass
Interventions: Mixed Meal Tolerance test, Hyperglycemic clamp; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 19 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: NIS793, Nab-paclitaxel, Gemcitabine, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Los Angeles, California • Orlando, Florida + 6 more

Conditions: Dietary Modification
Interventions: Tart cherry Juice, High-fat meal, Exercise; Dietary Supplement · Other
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Aging, Muscular Atrophy
Interventions: resistance training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Neurofibromatosis 1, Social Skills
Interventions: PEERS; Behavioral
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 12 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Islet After Kidney Transplant for Type 1 Diabetes

Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents

The RELAX Trial: Nonpharmaceutical Intervention for Nocturnal Muscle Cramps

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

ET-01 in Subjects With Lateral Canthal Lines

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Patient-Reported Outcome Questionnaire for Systemic Mastocytosis

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Omega 3 Fatty Acid Trial

Vitamin D Status in Lower Extremity Joint Replacement Surgery Patients

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Stimulating the Social Brain

Oxytocin, Emotions and Mirror Neurons

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

Non-Comparative Study of Open Abdomen That Require the Use of Negative Pressure Wound Therapy (NPWT) for Temporary Abdominal Closure

Hispanics With Metabolic Syndrome and Non-ischemic Heart Failure

Pilot Study Using Propranolol To Promote Prenylation Of Gtpase Rap1b In Hematopoietic Stem Cell Transplant Recipients

A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging

Glucose Metabolism in the Immediate and Short Term Follow up After Bariatric Surgery

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Antioxidant Responses to Exercise and Cherry Consumption

Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults

Pilot Randomized Control Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1